Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Alebund Pharmaceuticals (Jiangsu) Days Payable?
Alebund Pharmaceuticals (Jiangsu)HKSE:09637 -2.87%5 Days Payable is 989.60 as of Dec. 2025, which is 39% below its 10-year median of 1,635.42. GuruFocus rates HKSE:09637 with a GF Score™ of 5/100. The stock has 1 warning sign investors should review. Among 927 Drug Manufacturers companies, Alebund Pharmaceuticals (Jiangsu) ranks better than 96.87% on this metric.
The historical rank and industry rank for Alebund Pharmaceuticals (Jiangsu)'s Days Payable or its related term are showing as below:
HKSE:09637'
s Days Payable Range Over the Past 10 Years
Min: 989.6 Med: 1635.42 Max: 2281.23
Current: 989.6
During the past 2 years, Alebund Pharmaceuticals (Jiangsu)'s highest Days Payable was 2281.23. The lowest was 989.60. And the median was 1635.42.
HKSE:09637's Days Payable is ranked better than 96.87% of 927
companies
in the Drug Manufacturers industry
Industry Median: 88.13
vs HKSE:09637: 989.60
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alebund Pharmaceuticals (Jiangsu) Days Payable Chart
Alebund Pharmaceuticals (Jiangsu) Annual Data
Trend
Dec24
Dec25
Days Payable
2,281.23
989.60
Alebund Pharmaceuticals (Jiangsu) Semi-Annual Data
Dec24
Dec25
Days Payable
2,281.23
989.60
HKSE:09637 vs LLY, JNJ, ABBV: Days Payable Comparison
For the Drug Manufacturers - General subindustry, Alebund Pharmaceuticals (Jiangsu)'s Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alebund Pharmaceuticals (Jiangsu) Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alebund Pharmaceuticals (Jiangsu)'s Days Payable distribution charts can be found below:
* The bar in red indicates where Alebund Pharmaceuticals (Jiangsu)'s Days Payable falls into.
Alebund Pharmaceuticals (Jiangsu) Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alebund Pharmaceuticals (Jiangsu) (HKSE:09637) has a Days Payable of 989.60 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Alebund Pharmaceuticals (Jiangsu) and its competitors. This is 39% below median its historical median of 1,635.42. Over the past decade, Alebund Pharmaceuticals (Jiangsu)'s Days Payable has ranged from 989.60 to 2,281.23. According to the industry distribution chart, Alebund Pharmaceuticals (Jiangsu) ranks #29 out of 927 companies in the Drug Manufacturers industry, placing it in the top 3.1%.
Is Alebund Pharmaceuticals (Jiangsu)'s Days Payable too high?
Alebund Pharmaceuticals (Jiangsu)'s current Days Payable of 989.60 is 39% below median its 10-year median of 1,635.42. Over the past 10 years, this metric has ranged from a low of 989.60 to a high of 2,281.23. The Drug Manufacturers industry median Days Payable is 88.13. Alebund Pharmaceuticals (Jiangsu)'s value of 989.60 is 1022.9% above this industry median. Based on the distribution chart, Alebund Pharmaceuticals (Jiangsu) ranks #29 out of 927 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Alebund Pharmaceuticals (Jiangsu) has a GF Score™ of 5/100, reflecting its overall financial health beyond just this single metric.
How does Alebund Pharmaceuticals (Jiangsu)'s Days Payable compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Alebund Pharmaceuticals (Jiangsu) ranks #29 out of 927 companies for Days Payable. This places Alebund Pharmaceuticals (Jiangsu) in the top 3% of its industry — outperforming the majority of peers. The industry median Days Payable is 88.13. Alebund Pharmaceuticals (Jiangsu)'s value of 989.60 is 1022.9% above this benchmark. Historically, Alebund Pharmaceuticals (Jiangsu)'s own Days Payable has ranged from 989.60 to 2,281.23 over the past decade. While the company's 10-year median is 1,635.42 vs. the industry median of 88.13, Alebund Pharmaceuticals (Jiangsu) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 88.13, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alebund Pharmaceuticals (Jiangsu)'s current Days Payable of 989.60 is 1022.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Alebund Pharmaceuticals (Jiangsu) and its competitors. For the Drug Manufacturers industry, the median Days Payable is 88.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alebund Pharmaceuticals (Jiangsu)'s current Days Payable is 989.60, which is 39% below median its own 10-year median of 1,635.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alebund Pharmaceuticals (Jiangsu) stock overvalued right now?
Alebund Pharmaceuticals (Jiangsu) (HKSE:09637) has a current Days Payable of 989.60. The current Days Payable is 989.60, which is 39% below median its 10-year median of 1,635.42 and 1022.9% above the Drug Manufacturers industry median of 88.13. Alebund Pharmaceuticals (Jiangsu)'s overall GF Score™ is 5/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Alebund Pharmaceuticals (Jiangsu) (HKSE:09637), the current Days Payable is 989.60 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alebund Pharmaceuticals (Jiangsu) Ltd is a biopharmaceutical company. Along with its subsidiaries, the company is principally engaged in the development, manufacturing, and commercialization of renal products. Its product portfolio in clinical and preclinical stages consists of one Core Product AP301 and six other product candidates, including one late-clinical-stage product candidate AP306, one early-clinical-stage product candidate (AP303), and four preclinical product candidates (AP308, AP304, AP305, and AP307). The company generated revenue from the sales of Mircera in China, a product used in the treatment of renal anemia.
5GF Score
Get the complete analysis for HKSE:09637
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:09637 has been successfully added to your 
